

Pityriasis following COVID-19 vaccinations: a systematic review

Laura Duzett, Guadalupe Mercado, Vasiliki Tasouli-Drakou, Alicia Kane, Alison Tam

SUPPLEMENTARY MATERIAL

Table 1. Summary of patient demographics, vaccine types and doses prior to onset of reaction, developed pityriasis subtype, time to onset of symptoms and duration of reaction following COVID-19 vaccination.

Publication	Patient demographics		Vaccine type	1 st , 2 nd , or booster dose	Pityriasis variant	Time to onset of symptoms (days)	Duration of reaction (weeks unless else noted)
	Age	Sex					
Abdullah <i>et al.</i> (2021)	40	M	Unspecified m-RNA	2	PR	7	3
Adya <i>et al.</i> (2020)	21	M	AstraZeneca	1	PR	4	NR
Ajebo <i>et al.</i> (2022)	75	M	Moderna	1 & 2	PRP	3	26-week follow-up showed incomplete improvement*
Akdaş <i>et al.</i> (2021)	45	F	Coronavac	1 & 2	PR	4	3 (first dose), 1 (second dose)
Al Muqrin <i>et al.</i> (2022)	31	M	Pfizer-BioNTech	1	PLC	30	NR
Bin Rubaian <i>et al.</i>	15	F	Pfizer-BioNTech	2	PR	2	3

(2022)							
Bostan <i>et al.</i> (2022)	34	F	Unspecified m-RNA	2	PR	15	NR
Buckley <i>et al.</i> (2022)	23	F	Pfizer-BioNTech	1	PR	7	NR
Busto-Leis <i>et al.</i> (2021)	29	M	Pfizer-BioNTech	2	PR	7	NR
	26	M	Pfizer-BioNTech	2	PR	1	NR
Carballido <i>et al.</i> (2021)	35	M	Pfizer-BioNTech	1	PR-like	NR	2
Cohen <i>et al.</i> (2022)	66	M	Pfizer-BioNTech	1	PR	7	4
Criado <i>et al.</i> (2022)	31	M	AstraZeneca	1	PRP	10	12
	42	M	AstraZeneca	2	PRP	8	12
Cyrenne <i>et al.</i> (2022)	20	F	Pfizer-BioNTech	1 & 2	PR-like	NR	2
	40	M	Pfizer-BioNTech	2	PR-like	2	3
Dawoud <i>et al.</i> (2022)	16	M	Pfizer-BioNTech	1 & 2	PLC	7	14
Dormann <i>et al.</i> (2021)	19	F	AstraZeneca	1	PR	12	2
Drago <i>et al.</i> (2022)	47	M	Pfizer-BioNTech	1 & 2	PLC	7	4
Fenner <i>et al.</i> (2022)	56	F	johnson and	1	PR	7	2

			johnson				
Fernández <i>et al.</i> (2021)	59	M	Coronavac	2	PRP	4	NR
	56	M	Coronavac	2	PRP	30	NR
Filippi <i>et al.</i> (2022)	72	M	AstraZeneca	1	PLEVA	14	NR
Gambichler <i>et al.</i> (2022)	51	M	Spikevax/Moderna	Booster	PRP	10	NR
Gamonal <i>et al.</i> (2022)	47	M	Pfizer-BioNTech	Booster	PRP	15	NR*
Gökçek <i>et al.</i> (2022)	68	M	Coronavac	1	PR	10	NR
Hlaca <i>et al.</i> (2022)	85	F	Pfizer-BioNTech	Booster	PRP	7	16
Huang <i>et al.</i> (2022)	19	M	Inactivated COVID-19 vaccine produced by Beijing Institute of Biological Products Company.	1	PR	2	1
	51	M	Inactivated COVID-19 vaccine produced by Beijing Institute of Biological Products Company.	2	PR	7	NR

Hunjan <i>et al.</i> (2021)	51	M	Pfizer-BioNTech	1 & 2	PRP	3	4 months*
Khattab <i>et al.</i> (2022)	49	F	Pfizer-BioNTech	1	PR	8	4
	53	M	Pfizer-BioNTech	2	PR	7	4
Leerunyakul <i>et al.</i> (2021)	52	F	AstraZeneca	1	PR	14	1
LeWitt <i>et al.</i> (2022)	54	F	Pfizer-BioNTech	1 & 2	PLEVA	14	3
Liu <i>et al.</i> (2022)	67	M	Coronavac	1 & 2	PRP	7	12
Lladó <i>et al.</i> (2021)	63	F	AstraZeneca	1	PRP	9	NR
Mäkilä <i>et al.</i> (2022)	21	F	Pfizer-BioNTech	2	PLEVA	10	8
Marcantonio-Santa Cruz <i>et al.</i> (2021)	54	F	Pfizer-BioNTech	1 & 2	PR	7	3
	22	F	Pfizer-BioNTech	2	PR	7	NR
Martora <i>et al.</i> (2022)	46	F	Moderna	1	PR	6	NR
	49	M	Moderna	1	PR	7	NR
	24	F	Moderna	1	PR	11	NR
Mehta <i>et al.</i> (2022)	24	M	AstraZeneca	1	PR	1	NR**
Palmén <i>et al.</i> (2022)	81	M	Pfizer-BioNTech	1	PLEVA	9	20
Pedrazini <i>et al.</i> (2021)	53	F	AstraZeneca	2	PR	15	8

Ramot <i>et al.</i> (2020)	51	F	Pfizer-BioNTech	2	PR	3	4-6
	20	M	Pfizer-BioNTech	1	PR	3	4-6
	26	M	Pfizer-BioNTech	2	PR	2	4-6
	23	F	Pfizer-BioNTech	1	PR	2	4-6
	66	M	Pfizer-BioNTech	2	PR	5	4-6
	23	M	Pfizer-BioNTech	1	PR	10	4-6
Sahni <i>et al.</i> (2022)	72	M	AstraZeneca	1	PRP	21	4-6
Sechi <i>et al.</i> (2022)	62	F	Moderna	1	PRP	5	NR
	82	F	Pfizer-BioNTech	1	PRP	7	NR
	70	M	Pfizer-BioNTech	2	PLEVA	5	10
Sernicola <i>et al.</i> (2022)	31	F	Pfizer-BioNTech	1	PLEVA	10	8
Shakoei <i>et al.</i> (2022)	54	M	Sinopharm	1	PLEVA	27	NR
	45	M	Sinopharm	Booster	PR	14	NR
Shin <i>et al.</i> (2022)	29	M	Moderna	2	PR	1	NR
Singh <i>et al.</i> (2022)	24	M	Covaxin	1	PR	5	3
Temiz <i>et al.</i> (2021)	57	M	Coronavac	2	PR	10	4
	42	F	Pfizer-BioNTech	1	Atypical PR	21	6
	26	M	Coronavac	2	Atypical PR	8	5

	61	F	Pfizer-BioNTech	1	Atypical PR	9	9
	44	M	Coronavac	2	Atypical PR	16	4
	56	F	Pfizer-BioNTech	1	Atypical PR	18	7
	58	M	Coronavac	2	PR	21	8
	42	M	Pfizer-BioNTech	1	PR	7	6
	32	M	Coronavac	2	PR	3	6
	29	M	Pfizer-BioNTech	1	PR	5	8
	46	M	Coronavac	1	PR	18	9
	52	M	Pfizer-BioNTech	1	PR	19	11
	38	M	Pfizer-BioNTech	1	PR	12	12
	45	M	Coronavac	2	PR	8	3
	59	M	Coronavac	1	PR	17	12
	29	F	Pfizer-BioNTech	2	PR	13	4
	46	F	Coronavac	1	PR	14	15
	59	F	Coronavac	2	PR	9	7
	31	F	Pfizer-BioNTech	2	PR	15	6
	47	F	Coronavac	1	PR	16	8
	52	F	Pfizer-BioNTech	1	PR	21	11
	28	F	Coronavac	1	PR	23	9

	27	F	Pfizer-BioNTech	2	PR	4	4
	59	F	Coronavac	2	PR	9	5
	48	F	Pfizer-Biontech	2	PR	5	3
	46	F	Coronavac	1	PR	9	14
	48	F	Pfizer-BioNTech	1	PR	16	12
	36	F	Coronavac	1	PR	14	9
	47	M	Coronavac	1	PR	12	11
	52	F	Pfizer-BioNTech	1	PR	11	8
	49	F	Coronavac	1	PR	10	7
Valk <i>et al.</i> (2021)	30	F	Pfizer-BioNTech	2	PR	3	NR
Wada <i>et al.</i> (2022)	65	M	AstraZeneca	1	PRP	2	NR
Wang <i>et al.</i> (2022)	40	M	Moderna	1	PR	7	NR

M, male; F, female; PR, Pityriasis Rosea; PLEVA, Pityriasis Lichenoides et Varioliformis Acuta; PRP, Pityriasis Rubra Pilaris; NR, not reported; *patient was continuing treatment at the time of publication of the case study; **patient was lost to follow-up.

Table S2. Quality Assessment of publications. The maximum score a case study could achieve was a score of 16.

Publication	Total score
Abdullah <i>et al.</i> (2021)	14
Adya <i>et al.</i> (2020)	10
Ajebo <i>et al.</i> (2022)	14
Akdaş <i>et al.</i> (2021)	15
Al Muqrin <i>et al.</i> (2022)	12
Bin Rubaian <i>et al.</i> (2022)	14
Bostan <i>et al.</i> (2022)	13
Buckley <i>et al.</i> (2022)	12
Busto-Leis <i>et al.</i> (2021)	9
Carballido <i>et al.</i> (2021)	12
Cohen <i>et al.</i> (2022)	15
Criado <i>et al.</i> (2022)	14
Cyrenne <i>et al.</i> (2022)	14
Dawoud <i>et al.</i> (2022)	15
Dormann <i>et al.</i> (2021)	10
Drago <i>et al.</i> (2022)	12
Fenner <i>et al.</i> (2022)	15
Fernández <i>et al.</i> (2021)	14

Filippi <i>et al.</i> (2022)	15
Gambichler <i>et al.</i> (2022)	12
Gamonal <i>et al.</i> (2022)	14
Gökçek <i>et al.</i> (2022)	13
Hlaca <i>et al.</i> (2022)	14
Huang <i>et al.</i> (2022)	14
Hunjan <i>et al.</i> (2021)	15
Khattab <i>et al.</i> (2022)	15
Leerunyakul <i>et al.</i> (2021)	14
LeWitt <i>et al.</i> (2022)	15
Liu <i>et al.</i> (2022)	16
Lladó <i>et al.</i> (2021)	12
Mäkilä <i>et al.</i> (2022)	12
Marcantonio-Santa Cruz <i>et al.</i> (2021)	14
Martora <i>et al.</i> (2022)	14
Mehta <i>et al.</i> (2022)	11
Palmén <i>et al.</i> (2022)	15
Pedrazini <i>et al.</i> (2021)	14
Ramot <i>et al.</i> (2020)	12

Sahni <i>et al.</i> (2022)	15
Sechi (2022)	15
Sernicola <i>et al.</i> (2022)	15
Shakoei <i>et al.</i> (2022)	12
Shin <i>et al.</i> (2022)	10
Singh <i>et al.</i> (2022)	14
Temiz <i>et al.</i> (2021)	14
Valk <i>et al.</i> (2021)	12
Wada <i>et al.</i> (2022)	13
Wang <i>et al.</i> (2022)	15